Mount Yale Investment Advisors LLC Has $657,000 Position in GSK plc (NYSE:GSK)

Mount Yale Investment Advisors LLC trimmed its holdings in GSK plc (NYSE:GSK) by 11.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,052 shares of the pharmaceutical company’s stock after selling 2,102 shares during the quarter. Mount Yale Investment Advisors LLC’s holdings in GSK were worth $657,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Dimensional Fund Advisors LP lifted its stake in GSK by 1.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,777,695 shares of the pharmaceutical company’s stock valued at $65,883,000 after buying an additional 18,585 shares during the period. Assetmark Inc. lifted its position in shares of GSK by 1,598.7% during the 4th quarter. Assetmark Inc. now owns 2,582 shares of the pharmaceutical company’s stock valued at $96,000 after acquiring an additional 2,430 shares during the period. Franklin Resources Inc. boosted its stake in GSK by 0.9% during the fourth quarter. Franklin Resources Inc. now owns 64,336 shares of the pharmaceutical company’s stock worth $2,451,000 after acquiring an additional 602 shares in the last quarter. US Bancorp DE grew its holdings in GSK by 3.3% in the fourth quarter. US Bancorp DE now owns 117,503 shares of the pharmaceutical company’s stock worth $4,355,000 after purchasing an additional 3,722 shares during the period. Finally, Neuberger Berman Group LLC increased its stake in GSK by 5.7% in the fourth quarter. Neuberger Berman Group LLC now owns 32,435 shares of the pharmaceutical company’s stock valued at $1,202,000 after purchasing an additional 1,763 shares in the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Stock Up 0.1 %

GSK stock opened at $40.86 on Tuesday. The firm has a market capitalization of $84.67 billion, a PE ratio of 14.80, a P/E/G ratio of 1.41 and a beta of 0.66. The company has a quick ratio of 0.54, a current ratio of 0.82 and a debt-to-equity ratio of 0.99. GSK plc has a twelve month low of $33.67 and a twelve month high of $45.92. The stock’s 50 day moving average is $41.43 and its 200-day moving average is $41.66.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.09. GSK had a return on equity of 51.48% and a net margin of 12.87%. The business had revenue of $9.95 billion for the quarter, compared to analysts’ expectations of $9.49 billion. Sell-side analysts expect that GSK plc will post 4.15 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 10th. Investors of record on Friday, August 16th will be issued a dividend of $0.3843 per share. The ex-dividend date of this dividend is Friday, August 16th. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 annualized dividend and a yield of 3.76%. GSK’s payout ratio is 54.71%.

Analyst Ratings Changes

GSK has been the topic of a number of research analyst reports. Argus raised shares of GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Berenberg Bank raised GSK to a “strong-buy” rating in a research note on Thursday, June 20th. Citigroup upgraded GSK to a “strong-buy” rating in a report on Monday, June 24th. The Goldman Sachs Group initiated coverage on GSK in a report on Thursday, May 30th. They issued a “neutral” rating and a $47.00 target price on the stock. Finally, UBS Group lowered shares of GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Four equities research analysts have rated the stock with a hold rating, two have issued a buy rating and four have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $50.00.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.